Profile data is unavailable for this security.
About the company
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
- Revenue in EUR (TTM)323.88m
- Net income in EUR8.85m
- Incorporated--
- Employees1.32k
- LocationLaboratorio Reig Jofre SAGran Capita, 10SANT JOAN DESPI 08970SpainESP
- Phone+34 934806710
- Websitehttps://reigjofre.com/es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avantium NV | 19.70m | -31.40m | 204.37m | 262.00 | -- | 2.87 | -- | 10.37 | -0.631 | -0.631 | 0.3851 | 0.8947 | 0.1005 | 2.27 | 1.84 | 75,190.84 | -17.42 | -23.26 | -23.76 | -30.61 | 83.07 | 83.15 | -173.35 | -186.67 | 1.00 | -- | 0.6689 | -- | 10.51 | 11.79 | -11.64 | -- | 61.87 | -- |
| Innate Pharma SA | 51.90m | -7.57m | 204.58m | 179.00 | -- | 3.94 | -- | 3.94 | -0.0939 | -0.0939 | 0.6451 | 0.642 | 0.2648 | -- | 5.67 | 289,949.70 | -3.86 | -8.83 | -4.87 | -12.11 | 94.50 | 93.17 | -14.59 | -55.55 | -- | -- | 0.6408 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Egetis Therapeutics AB (publ) | 5.50m | -28.64m | 207.09m | 30.00 | -- | 5.00 | -- | 37.64 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| 4Basebio PLC | 416.01k | -7.37m | 210.68m | -- | -- | 50.56 | -- | 506.42 | -0.5094 | -0.5094 | 0.0287 | 0.2769 | 0.0296 | 0.3977 | 4.88 | -- | -52.42 | -- | -60.21 | -- | 80.51 | -- | -1,772.60 | -- | 3.28 | -40.29 | 0.6683 | -- | -20.71 | -- | -59.20 | -- | -- | -- |
| BioInvent International AB | 5.36m | -29.30m | 213.01m | 109.00 | -- | 1.97 | -- | 39.76 | -5.08 | -5.08 | 0.929 | 18.73 | 0.041 | -- | 1.29 | 550,927.90 | -22.41 | -17.50 | -23.68 | -18.64 | -- | -- | -547.02 | -131.63 | 13.34 | -- | 0.0169 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
| hVIVO PLC | 65.86m | 18.94m | 214.28m | 274.00 | 11.46 | 5.31 | 9.68 | 3.25 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Vicore Pharma Holding AB | 9.13m | -18.65m | 215.32m | 26.00 | -- | 5.03 | -- | 23.58 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Probi AB | 53.22m | -52.74k | 217.60m | 167.00 | -- | 1.74 | 25.88 | 4.09 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Genovis AB | 11.13m | 2.69m | 219.36m | 36.00 | 81.62 | 12.21 | 60.42 | 19.72 | 0.4686 | 0.4686 | 1.94 | 3.13 | 0.5084 | -- | -- | 3,432,784.00 | 12.28 | 18.56 | 13.37 | 21.45 | 66.09 | 65.51 | 24.15 | 23.88 | -- | -- | 0.2769 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| Allergy Therapeutics plc | 62.59m | -59.01m | 226.86m | 635.00 | -- | 7.30 | -- | 3.62 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Sensorion SA | 0.00 | -22.06m | 231.79m | 50.00 | -- | 4.34 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
| Genfit SA | 38.18m | -28.89m | 235.35m | 159.00 | -- | 3.46 | -- | 6.16 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Laboratorio Reig Jofre SA | 323.88m | 8.85m | 237.10m | 1.32k | 26.27 | 1.12 | 10.53 | 0.732 | 0.1115 | 0.1115 | 4.11 | 2.63 | -- | -- | -- | 246,110.20 | -- | 2.14 | -- | 2.79 | 58.04 | 61.39 | 2.73 | 2.65 | 0.8906 | 7.22 | 0.2219 | -- | 16.57 | 11.86 | 16.04 | 0.3019 | -9.54 | -- |
| Alliance Pharma plc | 199.84m | -8.30m | 246.40m | 249.00 | -- | 0.7567 | 66.95 | 1.23 | -0.0131 | -0.0131 | 0.3145 | 0.5127 | 0.3202 | 2.88 | 4.40 | 682,927.70 | -1.33 | 2.64 | -1.47 | 2.95 | 57.58 | 63.38 | -4.15 | 8.35 | 1.38 | 2.18 | 0.31 | 53.41 | 2.58 | 10.50 | -87.21 | -49.62 | -25.78 | 5.94 |
| Bioventix PLC | 15.98m | 10.18m | 263.76m | 16.00 | 26.34 | 19.63 | 25.54 | 16.51 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
| PharmaSGP Holding SE | 107.29m | 18.11m | 268.80m | 89.00 | 14.83 | 6.01 | 9.77 | 2.51 | 1.51 | 1.51 | 8.95 | 3.73 | 0.7818 | 1.06 | 9.12 | 1,205,539.00 | 13.20 | 13.70 | 16.44 | 19.98 | 90.93 | 90.20 | 16.88 | 17.56 | 2.19 | 12.34 | 0.6237 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
Data as of May 31 2024. Currency figures normalised to Laboratorio Reig Jofre SA's reporting currency: Euro EUR
4.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Quaero Capital SAas of 27 Feb 2024 | 2.39m | 3.01% |
| Solventis SGIIC SAas of 31 Dec 2023 | 282.56k | 0.36% |
| Andbank Wealth Management SGIIC SAUas of 31 Dec 2023 | 225.20k | 0.28% |
| Quadriga Asset Managers SGIIC SAas of 31 Dec 2023 | 155.00k | 0.20% |
| GVC Gaesco Gesti�n SGIIC SAas of 31 Mar 2024 | 126.51k | 0.16% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 25.11k | 0.03% |
| Euroagentes Gesti�n SGIIC SAas of 31 Dec 2023 | 12.31k | 0.02% |
| Renta 4 Gestora SGIIC SAas of 31 Dec 2023 | 6.00k | 0.01% |
| Dimensional Fund Advisors Ltd.as of 09 May 2024 | 5.91k | 0.01% |
More ▼
Data from 31 Dec 2023 - 30 May 2024Source: FactSet Research Systems Inc.
